First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer
Blagden S, Spicer J, Twelves C, Jones K, Prince J, Inatani M, Shiokawa R, Noguchi K, Pope L, Riisnaes R, Swales K, Decordova S, Anthoney A, Pinato D, Zivi A, Stavraka C, Josephs D, Omlin A, Banerji U. First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. Clin Cancer Res 2014; 20:5908-17.
Sep 17, 2014
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer
Sep 17, 2014
Clin Cancer Res 2014; 20:5908-17
Blagden Sarah, Spicer James, Twelves Chris, Jones Keith, Prince Jenny, Inatani Michiyasu, Shiokawa Rie, Noguchi Kohei, Pope Lorna, Riisnaes Ruth, Swales Karen, Decordova Shaun, Anthoney Alan, Pinato David J, Zivi Andrea, Stavraka Chara, Josephs Debra, Omlin Aurelius, Banerji Udai
more
